Profile of the progesterone derivative chlormadinone acetate - pharmocodynamic properties and therapeutic applications.

@article{Druckmann2009ProfileOT,
  title={Profile of the progesterone derivative chlormadinone acetate - pharmocodynamic properties and therapeutic applications.},
  author={Ren{\'e} A Druckmann},
  journal={Contraception},
  year={2009},
  volume={79 4},
  pages={272-81}
}
Chlormadinone acetate (CMA) is a derivative of progesterone (17alpha-acetoxy-6-chloro-4,6-pregnadiene-3,20-dione), first synthesized in 1961 and is used as an orally effective progestogen in hormone replacement therapy (HRT), and in combination with ethinyl estradiol (EE) in contraception since 1999. Chlormadinone acetate has a strong progestogenic effect - about one-third higher than that of progesterone - and may vary depending on the previous effect of an estrogen, i.e., estrogens may… CONTINUE READING
7 Citations
77 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 77 references

Administration prolongée d'acétate de chlormadinone: effets métaboliques, tensionnels et hormonaux

  • C Pelissier, A Basdevant, J Conard
  • Gynécologie
  • 1991
Highly Influential
6 Excerpts

Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study

  • G Schramm, D. Steffens
  • Clin Drug Invest 2002;22:221–31
  • 2002
Highly Influential
5 Excerpts

) 272 – 281 usage ( up to 45 cycles ) — an open - label , prospective , noncontrolled , office - based Phase III study

  • H Zahradnik, J Goldberg, J Andreas
  • 2009

Similar Papers

Loading similar papers…